drugset / Trial / NCT00439725

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (deep vein thrombosis) or PE (pulmonary embolism) who completed 6 or 12 months of treatment with rivaroxaban or VKA (vitamin K antagonist) are eligible for this trial (Einstein-Extension study).

Timeline

Start
2007-02
Primary completion
2009-08
Completion
2009-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 20 mg Oral